Figures & data
Figure 1. The multifaceted effects of doxorubicin on antitumor immunity. As it depletes myeloid-derived suppressor cells (MDSCs), promotes the immunogenic demise of cancer cells, and improves the activity of effector lymphocytes, doxorubicin may be efficiently combined with the adoptive transfer of helper T cells.
